Related Experiment Video

Updated: Jun 7, 2026

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes
08:19

In Vitro Assessment of Cardiac Function Using Skinned Cardiomyocytes

Published on: June 22, 2020

Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure

Christopher C Glembotski1

  • 1The SDSU Heart Institute and the Department of Biology, San Diego State University, San Diego, CA 92182, USA. cglembotski@sciences.sdsu.edu

Journal of Molecular and Cellular Cardiology
|October 26, 2010
PubMed

Insights

Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a novel cardiomyokine. It protects the ischemic heart and may offer new therapies for heart disease.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Cardiomyokines are heart-secreted proteins influencing cardiovascular function.
  • Mesencephalic astrocyte-derived neurotrophic factor (MANF) is identified as a novel cardiomyokine.
  • MANF expression increases in ischemic hearts, potentially via ER stress pathways.

Purpose of the Study:

  • To review the role of MANF as a cardiomyokine.
  • To explore MANF's function in the context of ER stress and ischemic heart disease.
  • To assess MANF's therapeutic potential for cardiovascular conditions.

Main Methods:

  • Literature review of studies on MANF, cardiomyokines, and ischemic heart disease.
  • Analysis of MANF expression patterns in response to ER stress.
  • Evaluation of existing data on MANF's protective effects in cardiovascular models.

Main Results:

  • MANF expression is upregulated in ischemic hearts, even under ER stress conditions that inhibit other cardiomyokines.
  • MANF demonstrates protective effects against ischemic damage.
  • MANF exhibits anti-hypertrophic properties.

Conclusions:

  • MANF functions as a cardiomyokine with significant roles in the stressed, ischemic heart.
  • MANF's unique behavior under ER stress highlights its importance.
  • MANF presents translational potential as a therapeutic agent for ischemic heart disease.

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...